Cargando…

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties

Triterpenoids have been used for medicinal purposes in many Asian countries because of their anti-inflammatory, antioxidant, antiproliferative, anticancer, and anticarcinogenic properties. Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yan-Yang, Yang, Yin-Xue, Zhe, Hong, He, Zhi-Xu, Zhou, Shu-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211867/ https://www.ncbi.nlm.nih.gov/pubmed/25364233 http://dx.doi.org/10.2147/DDDT.S68872

Ejemplares similares

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells
por: Wang, Yan-Yang, et al.
Publicado: (2015)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

Bardoxolone methyl: drug development for diabetic kidney disease
por: Kanda, Hironori, et al.
Publicado: (2020)

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
por: Ball, Michael S., et al.
Publicado: (2016)

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages
por: Torres, Gretel M., et al.
Publicado: (2022)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
por: Chi, Ying Lin, et al.
Publicado: (2023)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
por: Ball, Michael S., et al.
Publicado: (2020)

Bardoxolone methyl ameliorates osteoarthritis by inhibiting osteoclastogenesis and protecting the extracellular matrix against degradation
por: Yang, Ruijia, et al.
Publicado: (2023)

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease
por: Sun, Qi, et al.
Publicado: (2021)

CDDO-Me reveals USP7 as a novel target in ovarian cancer cells
por: Qin, Dongjun, et al.
Publicado: (2016)

Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
por: Qin, Dong-Jun, et al.
Publicado: (2015)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
por: El-Ashmawy, Mariam, et al.
Publicado: (2014)

Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice
por: Dinh, Chi H. L., et al.
Publicado: (2015)

Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
por: Nagasu, Hajime, et al.
Publicado: (2019)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents
por: Luo, Wanhe, et al.
Publicado: (2019)

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Bardoxolone Methyl Ameliorates Myocardial Ischemia/Reperfusion Injury by Activating the Nrf2/HO-1 Signaling Pathway
por: Huang, Anwu, et al.
Publicado: (2023)

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human
por: Yang, Fen, et al.
Publicado: (2017)

The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage
por: Amirova, Kristiana M., et al.
Publicado: (2023)

Pharmacokinetic-pharmacodynamic correlations in the development of ginger extract as an anticancer agent
por: Mukkavilli, Rao, et al.
Publicado: (2018)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells
por: Kurosaki, Yoshifumi, et al.
Publicado: (2022)

Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD
por: Lewis, James H., et al.
Publicado: (2020)

Bardoxolone conjugation enables targeted protein degradation of BRD4
por: Tong, Bingqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cvq3ps76187mh24jhap69cpuk2